Trials / Completed
CompletedNCT01289002
e-BioMatrix PostMarket Registry
A Postmarket Registry of the BioMatrix™ and BioMatrix Flex™ Drug Eluting Stents.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,652 (actual)
- Sponsor
- Biosensors Europe SA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this registry is to capture clinical data of the BioMatrix™ and BioMatrix Flex™ (Biolimus A9™-Eluting) stent systems in relation to safety and effectiveness.
Detailed description
Prospective, multi-center registry to be conducted at 60-70 international interventional cardiology centers. All patients will be followed for up to 3 years.
Conditions
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2012-09-01
- Completion
- 2014-09-01
- First posted
- 2011-02-03
- Last updated
- 2019-05-06
Locations
69 sites across 16 countries: Austria, Czechia, Denmark, France, Germany, Ireland, Jordan, Latvia, Lithuania, Morocco, Poland, Portugal, Russia, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT01289002. Inclusion in this directory is not an endorsement.